

Isabel Nahal Schellinger

VITA:

Studium	Medizinstudium an der Friedrich-Alexander-Universität Erlangen-Nürnberg Stanford University School of Medicine, Stanford, CA, USA
Promotion	<i>HIF Stabilization Improves Defective Ischemia-induced Angiogenesis in a Rodent Model of Chronic Kidney Disease</i> Universität Erlangen-Nürnberg, <i>summa cum laude</i>
Stationen	Klinik für Nephrologie, Universitätsklinikum Erlangen Cardiovascular Institute, Stanford University School of Medicine Karolinska Institutet, Stockholm Herzzentrum Göttingen Clinician-Scientist am Universitätsklinikum Leipzig
Aktuell	CEO und Mitgründerin von <i>Angiolutions</i> (Forschung- und Entwicklungsunternehmen im Bereich Gefäßmedizin)
Auszeichnungen	u.a. Bayerische EliteAkademie, Boehringer Ingelheim Fonds MD-Fellowship, Forbes 30 Under 30 - Europe - Science & Healthcare, MIT Technology Review Under 35, Einladung zur Lindauer Nobelpreisträger Tagung

VITA:

Education Friedrich-Alexander-University Erlangen-Nürnberg, Medical School
Stanford University School of Medicine, Stanford, CA, USA

Doctorate *HIF Stabilization Improves Defective Ischemia-induced Angiogenesis in a Rodent Model of Chronic Kidney Disease*
Friedrich-Alexander-University Erlangen-Nürnberg, *summa cum laude*

Positions Department of Nephrology, University Medical Center Erlangen, Germany
Cardiovascular Institute, Stanford University School of Medicine, CA, USA
Karolinska Institutet, Stockholm, Sweden
Heart Center Göttingen, Germany
Clinician-Scientist at the University Medical Center Leipzig

Currently **CEO and Co-Founder of *Angiolutions* (Medical R&D enterprise)**

Recognitions e.g., Bavarian EliteAkademie, Boehringer Ingelheim Fonds MD-Fellowship, Forbes 30 Under 30 - Europe - Science & Healthcare, MIT Technology Review Under 35, Invitee Lindau Nobel Laureate Meeting